Pharmacology Of Older Adults Flashcards
Antidepressants and antipsychotic medications that have anticholinergic burden?
“TO PACC”
TCAs
Olanzapine
Paroxetine
Antipsychotics/antidepressants
Chlorpromazine
Clozapine
Incontinence medications that have an anticholinergic burden?
“SOFTi”
Solifenacin
Oxybutynin
Fesoterodine
Tolterodine
Incontinence
Antihistamine medications that have an anticholinergic burden?
“MD ACHe”
Meclizine
Diphenhydramine
Antihistamines
Chlorphreniramine
Hydroxyzine
Anti-Parkinson’s medications that have an anticholinergic burden?
“TAB”
Trihexyphenidyl
Anti-Parkinson’s
Benztropine
Antispasmodic medications that have an anticholinergic burden?
“DASH”
Dicyclomine
Antispasmodics
Scopolamine
Hyoscyamine
Medication classes that have medication-causing sedative burden?
Antidepressants/antipsychotics
Antiseizure
Antihistamines (1st gen > 2nd gen)
Sedative hypnotics
Muscle relaxers
Opioids
Other (prazosin, terazosin, doxazosin, clonidine, levodopa, donepezil, atenolol, benztropine, indomethacin, metoclopramide)
Cardiovascular medication points to keep in mind for older adults
Downregulation of catecholamine receptors=decreased effectiveness of alpha/beta receptor antagonists
Increased sensitivity to QT-prolonging meds=increased risk of torsades de pointes
In pts >85 yo, strict control of HTN may not lead to improvement in outcomes; risk of death may be higher in individuals w/ BP <140/90 mmHg
Preferred agents for HTN
DHP calcium channel blockers (ex: amlodipine)
Thiazide diuretics (chlorthalidone preferred)
ACEi/ARB (when indicated)
Other agents for HTN
Beta blockers (decreased beta-adrenergic receptor function in older adults; appropriate when indicated)
Peripheral alpha-1 blockers/centrally-acting alpha agonists: doxazosin/prazosin/terazosin/clonidine; response does not appear to be diminished
Medications that commonly cause orthostatic HoTN (test Q per Dr. Wonderful)
Alpha blockers
Beta blockers
Calcium channel blockers
Tricyclic antidepressants
Antipsychotics
Diuretics
Direct vasodilators
Opioids
Atrial fibrillation recommendations
EAST-AFNET 4 (2020): rhythm control preferred in new onset, high CV risk pts
Amiodarone for afib
Avoid as first-line for afib d/t toxicities (thyroid disease, hepatic dysfunction, lung disease, neurologic abnormalities, and bradycardia)
May be appropriate if: pt has comorbid HF or left ventricular hypertrophy AND rhythm control is preferred to rate control
Digoxin for afib
Should not be used first-line for afib or HF (lacking evidence, narrow therapeutic window and reduced clearance in older adults is concerning)
Reserve for pts w/ HFrEF still symptomatic after maximizing BB, ACEi, and diuretic
HF checklist: things on the “yes” list
Tx fluid overload w/ loop diuretic (furosemide, torsemide, bumetanide)
HFpEF NYHA Class II/III + increased BNP: SGLT2i, MRA, can consider ARNI (sacubutril-valsartan)
HFrEF NYHA: BB (carvedilol, metoprolol succinate, or bisoprolol), ARNI/ACEi/ARB, MRA, SGLT2i
HF checklist: things on the “no” list
Fluid retention/HF exacerbation: verapamil, diltiazem, NSAIDs/COX-2 inhibitors, pioglitazone
Increased mortality: cilostazol, dronedarone
QT-prolongation risk: dextromethorphan-quinidine
STOPP criteria relevant recommendations for HTN/HF/Afib: beta blockers
In combo w/ verapamil or diltiazem (risk of heart block)
With symptomatic bradycardia (< 50/ min), type II heart block or complete heart block (risk of profound hypotension, asystole)
STOPP criteria relevant recommendations for HTN/HF/Afib: loops
As first line tx for HTN (there are safer and more effective alternatives available)
For LE edema w/o: HF, liver failure, nephrotic syndrome or renal failure (use leg elevation/ compression hosiery)
For tx of HTN w/ concurrent urinary incontinence (may exacerbate)
STOPP criteria relevant recommendations for HTN/HF/Afib: thiazides
With current significant: hypokalemia, hyponatremia, hypercalcemia
With a hx of gout (can be precipitated by thiazide)
STOPP criteria relevant recommendations for HTN/HF/Afib: RAAS agents
ACEi or ARBs in pts w/ hyperkalemia
Aldosterone antagonists w/ concurrent K-conserving drugs (w/o monitoring serum K)
STOPP criteria relevant recommendations for HTN/HF/Afib: others
Amiodarone as first-line antiarrhythmic in SVT (BB, CCB safer)
Digoxin in HFpEF
Verapamil/ diltiazem in NYHA Class III/V HF (may worsen)
PDE5 inhibitors (in severe HF, w/ nitrates)
Centrally-acting agents (less well tolerated by older people)
Antithrombotic recommendations: DOACs
First-line: apixaban
Avoid rivaroxaban for long-term tx of afib or VTE
Dabigatran “potentially” inappropriate
Warfarin: avoid for afib or VTE unless long-term use w/ >70% time-in-range
Antithrombotic recommendations: antiplatelets
Evaluate whether indicated, especially for primary prevention
Use caution w/ dual antiplatelet therapy (ASA + clopidogrel)
Few reasons to use regular-strength ASA or antiplatelet + anticoagulant
STOPP criteria for antithrombotics
Long-term aspirin at doses greater than 160mg per day
Aspirin w/ a past hx of peptic ulcer disease w/o concomitant PPI
Aspirin + clopidogrel as secondary stroke prevention (there are some exceptions; no evidence of added benefit over clopidogrel monotherapy)
Aspirin in combo w/ vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in pts w/ chronic afib
Antiplatelet agents w/ vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in pts w/ stable coronary, cerebrovascular or peripheral arterial disease
Statins in older adults?
Often appropriate to continue
Fine-tuning – consider changing simvastatin to another agent
D/c can be considered to reduce pill burden in late life
Initiation at a late age (e.g. 90 yo) may not provide benefit
Confusion/memory loss
Endocrine pharmacotherapy points to keep in mind for older adults
Older pts may have decreased hypoglycemia awareness
Different symptoms than typical in younger pts
Older adults are more likely to need emergency tx for hypoglycemic episodes
Consider relaxing goals when appropriate
Diabetes medication points to keep in mind
Increased incidence of hypoglycemia w/ sulfonylureas
Increased sensitivity/decreased clearance of insulin
Monitor GFR w/ metformin, SGLT2 use
Issues w/ transitions of care
SGLT21 safety points
Ex: canagliflozin, dapagliflozin, empagaflozin
Increased incidence of urogenital infections in older adults (Fournier’s gangrene) - skin checks extra important
Renal monitoring
Fluid balance
Euglycemic ketoacidosis
Hormone therapy safety points
Avoid estrogen/testosterone HRT (there are exceptions)
Thyroid, growth hormone
General points when considering insomnia medication
Older adults have higher risk of AEs from hypnotics
Excessive sedation, cognitive impairment, night wandering, agitation, balance issues/falls
Risk of “hangover” effects from sleep meds
Continually assess effectiveness - avoid stacking
Important to determine underlying cause: anxiety/depression, pain, sleep apnea, restless leg syndrome, meds (both sedating and stimulating), urination urges, poor sleep hygiene
Insomnia medications that are NOT recommended
Benzodiazepines, Z-drugs, TCAs (except doxepin <6 mg), first gen antihistamines (diphenhydramine), antipsychotics (quetiapine)
Alternatives for insomnia medications
Suvorexant/lemborexant, melatonin/ramelteon, trazodone, mirtazapine ≤15 mg, low dose doxepin
Insomnia non-pharmacological treatment options
CBT-I, sleep education, sleep hygiene, sleep restriction therapy, stimulus control therapy, counter-arousal measures
NSAIDs for pain?
Not recommended
Significant AEs: GI bleeding, peptic ulcer, increased BP, worsening HF, CV events, kidney injury
Alternatives to NSAIDs for pain management
Non-pharm tx, APAP, diclofenac gel (Voltaren)